Pharnext Successfully Raises €16 Million via Private Placement
Pharnext SA (Paris:ALPHA) (FR0011191287 - ALPHA), a biopharmaceutical company pioneering a new approach to the development of innovative drug combinations based on big genomic data and artificial intelligence, today announced that it successfully closed a €16 million private placement.
The private placement includes 725,513 shares with warrants attached (“ABSA”) subscribed by CB LUX, generating gross income of €6.058 million, and convertible bonds (“CB”) for gross quasi-equity of €10.0 million subscribed by the Chinese pharmaceutical partner Tasly.
The proceeds from the private placement will provide the Company with additional resources to fund its strategy and continue its growth in the perspective of the forthcoming results of the Phase 3 trial of its most advanced PLEODRUG™, PXT3003 in the treatment of Charcot-Marie-Tooth disease type 1A.
“We would like to sincerely thank our partners for their trust and continued support of our Company and its innovative technological platform, PLEOTHERAPY™” said Prof. Daniel Cohen, M.D., Ph.D., Co-Founder and Chief Executive Officer of Pharnext. “We are thrilled by the major strategic and clinical advances we have achieved in our programmes, and look forward to reporting the results of the Phase 3 trial of our first-in-class product PXT3003 for the treatment of Charcot-Marie-Tooth disease type 1A in the second half of 2018.”
PRIVATE PLACEMENT DETAILS
ABSA has been issued in accordance with the approval of the Board of Directors implemented according to the Eighth Resolution of the Shareholders’ Meeting of 28 June 2017 (the “Shareholders’ Meeting”), without pre-emptive subscription rights, to the Company CBLUX S.A.R.L, already a 16.3% shareholder in Pharnext prior to this operation Pharnext (but not represented on its Board of Directors), and in which it will own 21.4% after the issuance.
A total of 725,513 ABSAs were issued via private placement, with a price of each equal to €8.35 (including premium), and each comprising an ordinary share and an ordinary warrant (“BSA”). The 725,513 new shares will be entirely assimilated into existing Pharnext shares and will represent approximately 6.48% of the number of outstanding shares after the private placement. Each BSA entitles to subscribe for 0.20 ordinary Pharnext shares, representing an additional issuance of 145,102 shares with a maximum exercise price of €8.27 per share. The shares that may be issued on exercise of the BSAs represent approximately 1.30% of the number of shares issued before the private placement. The BSAs may be exercised within 5 years from issuance. In the event all BSAs are exercised, the gross resulting income for Pharnext will be approximately 2 million euros. The theoretical value of five BSA giving right to one Pharnext share would be equal to 35% of a share price under Black & Scholes model.
CB has been issued in accordance with the approval of the Board of Directors implemented according to the Tenth Resolution of the Shareholders’ Meeting, without pre-emptive subscription rights, to Tasly, a leading Chinese pharmaceutical group and partner of Pharnext, already shareholder in Pharnext prior to this operation (but not represented on its Board of Directors) and with a 3.4%of the share capital after the operation.
A total of 10 convertible bonds were issued, each with a par value of 1 million euros, representing a total nominal amount of 10 million euros and bearing interest at a rate of 6.9% per year. The convertible bonds have a maturity of 3 years from their date of issue, and may be converted prior to the maturity date at a conversion price of €13 per share, representing a premium of 57% over the weighted average price during the last three trading sessions prior to their date of issue (automatic conversion at a price of 13 euros per share where the market price exceeds this value, on average, during three consecutive months, or conversion by the bondholder at any time, at a price of 13 euros). At the maturity date, the amount payable in respect of the convertible bonds will either be reimbursed, or converted at a rate representing 80% of the average value of the share price on the market, weighted by volume observed over a period of the last 20 trading sessions preceding the maturity date. On this basis, the shares that may be issued on conversion of the CB represent approximately a maximum of 6.8% of the number of shares issued prior to the issuance of both CB and ABSA, or 14,58% together with the ABSA. The CB will not be listed or admitted for trading on the Euronext Growth Paris market.
Pursuant to Article 211-3 of the AMF (Autorité des Marchés Financiers) General Regulations, it should be noted that neither of the above-mentioned issues has resulted or will result in the drafting of a prospectus submitted to the AMF for approval.
Pharnext is an advanced clinical-stage biopharmaceutical company developing novel therapeutics for orphan and common neurodegenerative diseases that currently lack curative and/or disease-modifying treatments. Pharnext has two lead products in clinical development. PXT3003 is currently in an international Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status in Europe and the United States. The results of this trial are expected in the second half of 2018. PXT864 has generated positive Phase 2 results in Alzheimer’s disease. Pharnext has developed a new drug discovery paradigm based on big genomic data and artificial intelligence: PLEOTHERAPY™. The Company identifies and develops synergic combinations of drugs called PLEODRUG™ offering several key advantages: efficacy, safety and robust intellectual property. The Company was founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics and is supported by a world-class scientific team.
Pharnext is listed on Euronext Growth Stock Exchange in Paris (ISIN
For more information, visit www.pharnext.com.
This press release has been issued to fulfil Pharnext's permanent reporting obligations. It does not constitute a public offering, subscription offering or a solicitation in view of a public offering.
Chief Operating Officer
+33 (0)1 41 09 22 3030
Investor Relations (Europe)
MC Services AG
+49 211 529252 22
Investor Relations (U.S.)
Stern Investor Relations, Inc.
+1 212 362 1200
Financial Communication (France)
+33 (0)1 56 88 11 15
Media Relations (Europe)
+33 (0)1 44 54 36 66
Media Relations (U.S.)
+1 212 223 4017
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Invengo Releases Latest Version of Its ACUITY Digital Platform for Linen Inventory Management20.9.2018 08:00 | Pressemelding
Invengo today announced hot new improvements to its ACUITY digital platform, underscoring its commitment to help laundry groups, hotels and healthcare facilities take full control over their linen inventories, anywhere and at any time. This new milestone release is a significant leap forward from its previous version, taking linen professionals one step further with 100% automatic real-time linen stock visibility, enabling stock levels optimization and availability through cloud-based reporting, dashboards and data analysis. This latest version of ACUITY provides a superior full cloud-based, software-as-a-service (SaaS) offering for companies seeking a plug-and-play solution, significantly reducing total cost of ownership, technical complexity, and setup time, while providing users with instant access to their linen management platform through a web browser on any device. This eliminates the hassle of hosting and maintaining their own server and dealing with software updates while enjo
Alibaba Announces Smart Mobility Initiatives with Partners20.9.2018 07:17 | Pressemelding
Alibaba Group Holding Limited (NYSE: BABA) announced today a series of smart mobility initiatives in partnership with auto brands and technology service providers. The announcement was made during The Cloud Computing Conference, the company’s largest technology showcase, held over four days in Hangzhou, Alibaba’s home base. Partnering with Bosch on Automated Valet Parking Alibaba Cloud, the cloud-computing arm of Alibaba Group, and Bosch, a leading global supplier of technology services, announced plans to introduce Automated Valet Parking (AVP) solutions in China. Both parties will work together to enable the infrastructure-based, driverless parking solution. The technology is powered by software in a cloud and it will offer a fully automated valet parking service in the near future. As part of the cooperation, Bosch will provide its AVP technology, its experience in systems engineering and its IoT competencies. Alibaba Cloud, meanwhile, will share its technologies and its experience
Egon Zehnder and Mobius Executive Leadership Formalize Exclusive Strategic Partnership20.9.2018 06:01 | Pressemelding
Egon Zehnder, the world’s leadership advisory firm, has entered into a formal partnership with Mobius Executive Leadership, the US and Europe-based premier leadership development firm. The partnership combines the firms’ proprietary methods for accelerating the personal and professional development of senior executives and for stimulating an organization’s ability to transform. “Readiness to lead at the top levels in business and society today requires leaders develop a willingness to understand who they are and who they can become so that they can unlock their full potential – and help their organizations unleash their potential as well,” stated Jill Ader, Egon Zehnder’s Chair-Elect and Co-developer of the Executive Breakthrough Program. “Together with Mobius, we have found success in doing that.” Already collaborating for more than four years, the two firms’ new partnership formally combines Egon Zehnder’s deep leadership advisory experience to the world’s most influential leaders an
Twispay Teams up with Blue Air to Expand Digital Payments20.9.2018 06:00 | Pressemelding
Blue Air, the largest Romanian airline by scheduled passengers flown, and Twispay, Swiss-owned European payment processor and FinTech pioneer, today announced the availability of a payment integration partnership that allows a global clientele to complete online payments through Twispay’s payment services. The airline industry is massively time pressured. Airline companies have learned to adapt business and pricing models according to a wide range of wildly fluctuating variables, from sudden shifts in demand and operational costs to erratic weather patterns. Therefore, the reliability and flexibility of a payment processing integration are paramount. The ability to accept online payments quickly, safely, and with ease is crucial to any 21st - century venture, let alone an airline company. “It was essential for us to establish a partnership with a processing services player who understands and can handle a high volume of transactions and air-travel operational particularities. Additiona
Alibaba A.I. Labs Launches Hospitality Robot20.9.2018 04:00 | Pressemelding
The robotics industry is revolutionizing the world, and Alibaba A.I. Labs is raising the stakes in this cutting-edge industry with the announcement of launching service robots for the hospitality sector starting in October. The news was made at The Computing Conference 2018, which is scheduled for four days till September 22 in Hangzhou, China, the site of Alibaba’s headquarters. Alibaba A.I. Labs is the department leading consumer AI product development at Alibaba. Hotels have until now depended entirely on human labor. But the labs' service robot — from delivering meals to taking laundry to guests — demonstrates what guests can expect at hotels in the future. Guests talk to the robot via voice command, touch and hand gesture, and its responses are driven by AliGenie, the software that powers Alibaba A.I. Labs’ smart speaker, Tmall Genie. “We are excited by this tremendous development that is helping us bridge the gap between guest needs and the response time that they expect. Alibaba
Celltrion Signs 'Incubation' Agreement with Emory University for Development of New Drugs for Atherosclerosis20.9.2018 02:03 | Pressemelding
Celltrion, Inc. (KRX:068270) signed an ‘Incubation’ agreement with Emory University in Atlanta to support the research and development of new drug candidates for atherosclerosis. ‘Incubation’ agreement is one of the open innovation measures by which a company provides its internal resources and capabilities, such as research space and facility, manpower and business operation consulting, to an external research institute or startup so as to support the research and ensure autonomy of the research aimed at developing new drugs or next-generation technology on the condition that the company can preferentially discuss commercialization of the research output. Under the agreement, Celltrion will share Celltrion’s accumulated biologics development expertise with Emory University School of Medicine and the Wallace H. Coulter Department of Biomedical Engineering at Emory University and Georgia Institute of Technology, and provide research costs and manufacturing materials of new drug candidat